Literature DB >> 11535495

Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.

K Fujikawa1, H Suzuki, B McMullen, D Chung.   

Abstract

von Willebrand factor (vWF) is synthesized in megakaryocytes and endothelial cells as a very large multimer, but circulates in plasma as a group of multimers ranging from 500 to 10 000 kd. An important mechanism for depolymerization of the large multimers is the limited proteolysis by a vWF-cleaving protease present in plasma. The absence or inactivation of the vWF-cleaving protease results in the accumulation of large multimers, which may cause thrombotic thrombocytopenic purpura. The vWF-cleaving protease was first described as a Ca(++)-dependent proteinase with an apparent molecular weight of approximately 300 kd. Thus far, however, it has not been isolated and characterized. In this study, the purification of human vWF-cleaving protease from a commercial preparation of factor VIII/vWF concentrate by means of several column chromatographic steps, including 2 steps of heparin-Sepharose column, is reported. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the anion exchange and gel filtration column fractions showed that the vWF-cleaving protease activity corresponded to a protein band of 150 kd. After reduction, it migrated with an apparent weight of 190 kd. The amino terminal sequence of the 150-kd band was AAGGIL(H)LE(L)L(D)AXG(P)X(V)XQ (single-letter amino acid codes), with the tentative residues shown in parentheses. A search of the human genome sequence identified the vWF-cleaving protease as a new member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin type I motif) family of metalloproteinase. An active site sequence of HEIGHSFGLEHE (single-letter amino acid codes) was located at 150 residues from the N terminus of the protein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535495     DOI: 10.1182/blood.v98.6.1662

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  109 in total

1.  A new name in thrombosis, ADAMTS13.

Authors:  J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

2.  Pathogenesis and treatment of acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  Flora Peyvandi; Roberta Palla; Luca A Lotta
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

Review 3.  ADAMTS proteases: key roles in atherosclerosis?

Authors:  Rebecca C Salter; Tim G Ashlin; Alvin P L Kwan; Dipak P Ramji
Journal:  J Mol Med (Berl)       Date:  2010-07-22       Impact factor: 4.599

Review 4.  [Dermatologic aspects of anticoagulation].

Authors:  V Meyer; S W Schneider; T Görge
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

5.  Von Willebrand factor antigen and ADAMTS13 activity assay in pregnant women and severe preeclamptic patients.

Authors:  Dandan Zhang; Juan Xiao; Haoliang Huang; Juanjuan Chen; Tao Liu; Zongzhi Yin; Danping Gao; Qiong Liu; Jihui Ai; Suhua Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

6.  Dynamic force spectroscopy of glycoprotein Ib-IX and von Willebrand factor.

Authors:  Maneesh Arya; Anatoly B Kolomeisky; Gabriel M Romo; Miguel A Cruz; José A López; Bahman Anvari
Journal:  Biophys J       Date:  2005-03-11       Impact factor: 4.033

7.  The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor.

Authors:  Jihui Ai; Paula Smith; Shuwei Wang; Ping Zhang; X Long Zheng
Journal:  J Biol Chem       Date:  2005-06-23       Impact factor: 5.157

8.  Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.

Authors:  S G Shelat; P Smith; J Ai; X L Zheng
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

9.  Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience.

Authors:  Moon Ju Jang; So Young Chong; In-Ho Kim; Jee-Hyun Kim; Chul-Won Jung; Ja Young Kim; Ji-Chan Park; Sun Min Lee; Yeo-Kyeoung Kim; Ji-Eun Lee; Sung-Su Jang; Jin-Seok Kim; Deog-Yeon Jo; Dae-Young Zang; Young-Yiul Lee; Ho-Young Yhim; Doyeun Oh
Journal:  Int J Hematol       Date:  2011-02-03       Impact factor: 2.490

10.  Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation.

Authors:  Yoshiaki Chinen; Junya Kuroda; Muneo Ohshiro; Yuji Shimura; Shinsuke Mizutani; Hisao Nagoshi; Nana Sasaki; Ryuko Nakayama; Miki Kiyota; Mio Yamamoto-Sugitani; Tsutomu Kobayashi; Yosuke Matsumoto; Shigeo Horiike; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2013-03-14       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.